# An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors

> **NCT03864575** · PHASE2 · UNKNOWN · sponsor: **Cliniques universitaires Saint-Luc- Université Catholique de Louvain** · enrollment: 68 (estimated)

## Conditions studied

- Metastatic Cancer

## Interventions

- **DRUG:** Celecoxib 400 mg

## Key facts

- **NCT ID:** NCT03864575
- **Lead sponsor:** Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-08-15
- **Primary completion:** 2021-06-15
- **Final completion:** 2021-06-15
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2019-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03864575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03864575, "An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced " Cold " Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03864575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*